Literature DB >> 11087792

Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain.

J Woulfe1, H Hoogendoorn, M Tarnopolsky, D G Muñoz.   

Abstract

Using antibodies generated against the latent membrane protein 1 of Epstein-Barr virus, intense immunoreactivity of Lewy bodies (in PD and dementia with Lewy bodies) and glial cytoplasmic inclusions (in multiple system atrophy) was demonstrated. ELISA and Western blotting techniques confirmed that this immunolabeling was due to cross-reactivity of the antiviral antibody with alpha-synuclein, a neuronal protein implicated in the pathogenesis of PD. This example of cross-reactivity between Epstein-Barr virus and alpha-synuclein may bear implications for further elucidating infectious or autoimmune mechanisms in PD.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11087792     DOI： 10.1212/wnl.55.9.1398

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

2.  Expanding the spectrum of neurological disease associated with Epstein-Barr virus activity.

Authors:  M Kleines; J Schiefer; A Stienen; M Blaum; K Ritter; M Häusler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-15       Impact factor: 3.267

3.  Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.

Authors:  Rizwan S Akhtar; Joseph P Licata; Kelvin C Luk; Leslie M Shaw; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurochem       Date:  2018-06-10       Impact factor: 5.372

Review 4.  Viral parkinsonism.

Authors:  Haeman Jang; David A Boltz; Robert G Webster; Richard Jay Smeyne
Journal:  Biochim Biophys Acta       Date:  2008-08-12

Review 5.  The role of innate and adaptive immunity in Parkinson's disease.

Authors:  George T Kannarkat; Jeremy M Boss; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

6.  Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System.

Authors:  Chris Carter
Journal:  Int J Alzheimers Dis       Date:  2011-12-29

7.  Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein-Barr virus (EBV).

Authors:  Arif Ali; Abbas Khan; Aman Chandra Kaushik; Yanjie Wang; Syed Shujait Ali; Muhammad Junaid; Shoaib Saleem; William C S Cho; Xueying Mao; Dong-Qing Wei
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

8.  α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls.

Authors:  Lynnae M Smith; Mya C Schiess; Mary P Coffey; Andrea C Klaver; David A Loeffler
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

9.  Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls.

Authors:  Beatriz Alvarez-Castelao; Ana Gorostidi; Javier Ruíz-Martínez; Adolfo López de Munain; José G Castaño
Journal:  Front Aging Neurosci       Date:  2014-07-15       Impact factor: 5.750

10.  Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein.

Authors:  John Woulfe; Madison T Gray; Munisha S Ganesh; Jaap M Middeldorp
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.